Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...
Hosted on MSN
Oppenheimer Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Outperform Recommendation
Fintel reports that on July 29, 2025, Oppenheimer initiated coverage of Atai Life Sciences N.V. (NasdaqGM:ATAI) with a Outperform recommendation. Analyst Price Forecast Suggests 201.20% Upside As of ...
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (ATAI) (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the ...
5-year UG3/UH3 grant will fund the optimization and early-stage development of atai’s novel 5-HT2A/2C receptor agonists with non-hallucinogenic potential for opioid use disorder NEW YORK and AMSTERDAM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results